The subscription period has now begun for Iconovo's rights issue. The issue will finance continued partnership discussions around ICOpre, development of an intranasal semaglutide product for obesity, and support Amneal in the development of a generic Symbicort. The company's CEO Johan Wäborg visited BioStock's studio for a company presentation where he will, among other things, talk more about the progress in the development projects and the capital raising.
The content of BioStock's news and analysis is independent, but BioStock's operations are to some extent financed by companies in the industry. This post refers to a company from which BioStock has received funding.
We cover early-stage, growth-stage and late-stage investments. From business angels and seed investors driving medical breakthroughs, to investments empowering promising...
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
Unlock our premium content: Become a subscriber!
Create Account
